Priming a pen is not optional

The aseptic sequence is short and it is routinely compressed. Wash hands. Swab the vial stopper with alcohol and allow it to dry, because a wet stopper carries organisms into the vial on the needle. Swab the skin and allow that to dry too, both for antisepsis and because injecting through wet alcohol stings and is what people mistakenly attribute to the drug. Use a new needle. None of this is demanding, and all of it is what stands between a multi-dose vial and a contaminated one.

What the diluent changes, and what it does not

The diluent has no effect on the arithmetic and a substantial effect on everything else. Bacteriostatic water contains a preservative, conventionally benzyl alcohol at around nine tenths of a per cent, which inhibits microbial growth and is what makes repeated puncture of a multi-dose vial defensible. Sterile water for injection contains no preservative and offers no protection after the first puncture. Sodium chloride solution is isotonic and generally more comfortable on injection, and preserved and unpreserved presentations both exist.

The choice is therefore a sterility decision rather than a convenience one. A vial that will be entered more than once and kept for weeks is a different proposition from a single-use preparation, and the presence or absence of a preservative is the difference.

Two cautions belong here. Benzyl alcohol is not appropriate in all populations and is specifically avoided in neonates. And no preservative rescues poor technique: bacteriostatic means growth-inhibiting, not sterilising, and a stopper swabbed carelessly with a needle passed through a wet surface will introduce organisms that the preservative was never intended to handle. The diluent is a margin, not a permission.

Priming, and what skipping it costs

Pen devices require a priming step — commonly a dial to two units and an expulsion until a drop appears at the needle tip — before each injection. It serves two functions: expelling air that has accumulated in the cartridge and needle, and confirming that the device and needle are patent before a dose is dialled.

Skipping it produces an intermittent underdose. Air occupies part of the delivered volume, so some of the dialled dose is gas. Because the loss is variable and invisible, the person experiences an occasional week that felt different rather than a device error, and the habit erodes precisely because the feedback is unreliable.

Two adjacent points belong with it. A pen needle should be attached immediately before use and removed immediately after, because a needle left in place allows solution to leak out and air to be drawn in, which is how cartridges come to contain air in the first place. And the ten-second hold at the end of an injection — plunger fully depressed, needle still in the skin — exists because delivery is not instantaneous at these bore sizes, and withdrawing early leaves part of the dose on the skin. Both are omitted routinely.

Aseptic technique, in four steps

Wash hands. Swab the vial stopper with seventy per cent alcohol and let it dry. Swab the injection site and let that dry. Use a new sterile needle for every entry into the vial and every injection.

Each step has a reason that is worth knowing, because steps with unexplained reasons are the ones that get dropped. The stopper is the sterile barrier of a multi-dose vial and a needle passed through a contaminated or still-wet stopper carries organisms directly into the solution. Alcohol works by evaporation as much as by contact, so a wet surface has not been disinfected — and injecting through wet alcohol stings, which is frequently misattributed to the drug. A needle that has already pierced a rubber stopper is blunted and no longer sterile.

What none of this can do is make an unknown preparation safe. Aseptic technique protects a sterile solution from contamination during handling; it does not sterilise a solution that arrived contaminated, and it does nothing whatever about bacterial endotoxin, which is heat-stable, filter-passing and invisible to any purity assay. Research-use-only material is not manufactured, tested or released to any human sterility standard, and careful technique does not change that.

Storage, and the in-use period nobody can give you

Lyophilised peptide is generally stored refrigerated at two to eight degrees, and is considerably more stable dry than in solution — which is the entire reason it is supplied as a powder. After reconstitution, degradation proceeds by hydrolysis, oxidation, aggregation and adsorption to container surfaces, at rates depending on sequence, buffer, temperature, light exposure and headspace.¹

For licensed products the in-use period is established by formal stability testing and printed on the carton, commonly twenty-eight days for a pen in use. For a peptide reconstituted at home there is no such study, and the numbers circulating in this market are extrapolations from other molecules, other buffers and other containers.

Three practical points survive that uncertainty. Cold slows every degradation route, so refrigeration is unambiguously better than ambient storage. Agitation promotes aggregation, so a vial should be swirled or the diluent run down the wall rather than shaken. And repeated temperature cycling — out for a dose, back in the door of the fridge, out again — is worse than steady cold, which argues against storing a vial in the door.

Anybody quoting a precise expiry for a home-reconstituted peptide is quoting a guess. The Journal would rather say so than repeat a number that sounds authoritative.

Sharps disposal

A used needle is a biohazard to whoever encounters it next, most often a waste worker. In most jurisdictions disposal of sharps in household waste is prohibited, and in all of them it is a route by which a stranger is injured.

The mechanism is simple and free almost everywhere: a rigid, puncture-resistant sharps container, filled to the marked line and no further, returned to a community pharmacy, a local authority collection point, a needle-exchange service or a clinical waste scheme. Improvised containers — a detergent bottle, a coffee tin — are widely used and generally accepted by collection services when rigid and sealed, though a purpose-made container is inexpensive.

Needle-clipping devices exist and remove the sharp tip. They reduce but do not eliminate the hazard and do not remove the disposal obligation.

The Journal raises this for a specific reason. We have heard from readers with two or three years of accumulated sharps in a drawer, kept there because they did not know where to take them and did not want to explain what they were for. Collection services are not interested in the contents of your vials. That is a real barrier built entirely out of anticipated judgement, and it is worth naming so that it can be dismissed.

Needle reuse

Needle points are manufactured sharp, coated and single-use. A single insertion blunts and deforms the tip measurably; electron micrographs of reused needles show visible damage after one use and substantial deformation after several. Reuse is more painful, produces more tissue trauma, and is a documented risk factor for lipohypertrophy.²

It is also extremely common, for reasons that are economic rather than ignorant. Needles cost money, they are sometimes hard to obtain without a prescription, and the harm from reuse is cumulative and invisible rather than immediate. A person reusing a needle is usually making a rational short-term decision with a poorly signposted long-term cost.

Two aggravations are worth stating. A needle left attached to a pen between doses allows leakage out and air in, which is a dosing problem as well as a sterility one. And a needle reused into a vial blunts the stopper, coring rubber fragments into the solution over repeated entries.

The Journal reports the practice without moralising about it, and notes that of all the technique failures in this file, this is the one most responsive to needles simply being cheap and available.³

The tenfold error in detail

It arises from the fact that one hundred units and one millilitre are the same volume. A calculated injection volume of 0.1 mL is ten units. A person who reads 0.1 and draws to the mark labelled one has given a tenth of the intended dose; a person who reads ten units and draws to the 1.0 mL mark on a millilitre-graduated barrel has given ten times it.

The vector is almost always a syringe that is not an insulin syringe. Tuberculin syringes and general-purpose 1 mL syringes are the same length, the same colour and often the same price, and they are graduated in hundredths of a millilitre. Nothing about picking up the wrong one feels like an error.

Two structural defences work. Keep one syringe type and one barrel size, and buy them deliberately rather than taking whatever the supplier included. And express the dose in the units of the instrument in use — write "8 units" on the vial tape if you use insulin syringes, and never carry a millilitre figure and a unit figure in the same note where one can be read as the other.

The Journal treats this as the most important paragraph in the file. It is a boring failure with a large magnitude, which is the profile of most real harm in this market.

The arithmetic is only as good as the label

Every calculation above starts from a stated mass of peptide in the vial. For licensed product that figure is a release specification. For research-grade lyophilised powder it is a claim, and the difference matters because the claim sits at the front of every subsequent computation.

Two distinct quantities are involved. Chromatographic purity is the proportion of peptide-related material that is the intended peptide. Peptide content is the fraction of the vial mass that is peptide at all, the remainder being counter-ions, residual solvent, water and excipient. A vial can be ninety-nine per cent pure and contain materially less peptide than labelled, and content is the number that determines a dose.

The four independent services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — report purity routinely and content less consistently. Several vendors, among them WXT, SSA, CPC, SWB and MKM, publish per-batch reports; others publish nothing verifiable. Where content has not been measured, the labelled mass should be treated as an upper bound and the resulting dose figure as an estimate. That is unsatisfying and it is honest, and it is why the Journal has argued in Analytics for content and endotoxin as standard reported fields.

How the Journal reports technique

Two bodies of evidence underlie this file. Questions of tissue, depth, needle length and rotation come from the insulin injection-technique literature, which is large, well conducted and directly transferable because it concerns anatomy rather than any particular molecule. Questions of absorption by site, in-use stability and exposure come from the incretin literature, which is smaller and where we say so. Where we describe practice rather than evidence, the text states it.

We give arithmetic in full rather than in tables of pre-computed unit counts, deliberately. A pre-computed table is correct only for the concentration it was computed for, and the recurring error in this market is precisely the reuse of a correct number under changed conditions. A reader who can perform the four-line calculation is protected against a class of error that no table can prevent.

Nothing in this file is medical advice. The Journal does not recommend doses, products, diluents or suppliers, and cannot assess an individual. Several compounds discussed are sold for research use only, are not approved for human use in any jurisdiction, and are not manufactured or released to any human sterility, content or endotoxin standard. Injection technique is properly taught in person by a clinician or nurse, and this file is not a substitute for that.

A short glossary

Unit (U-100): ten microlitres. A volume, not an amount of drug. Concentration: mass per volume, here usually milligrams per millilitre. Dead space: volume retained in needle and hub after full depression of the plunger. Priming: expelling a small volume before dosing, to clear air and confirm flow.

Gauge: needle bore, inversely numbered — higher gauge is thinner. Subcutaneous: into the fat layer beneath the dermis. Intradermal: within the skin itself, which is what an oblique short needle risks. Intramuscular: into muscle beneath the subcutaneous layer.

Lipohypertrophy: thickened subcutaneous tissue from repeated injection, with blunted and variable absorption. Lipoatrophy: localised loss of subcutaneous fat, a different and now rare immune-mediated phenomenon. Bacteriostatic: inhibiting microbial growth, not sterilising. In-use period: the interval after first puncture during which a product remains within specification, established by stability testing.

The distinction between bacteriostatic and sterile, and the distinction between purity and content, account between them for a large share of the confused correspondence this desk receives.

Four things about this that are genuinely unestablished

First, the in-use stability of home-reconstituted peptides. No sequence-specific, buffer-specific, container-specific stability study exists for the great majority of what is sold in this market, and the figures in circulation are extrapolations.

Second, whether the injection-site interchangeability established for licensed acylated agonists holds for material of uncertain formulation. The mechanism suggests it should; nobody has measured it.

Third, the real-world frequency of the errors catalogued above. Our ranking comes from correspondence, which is a self-selected sample that over-represents people who noticed. The denominator is unknown.

Fourth, whether any of the technique measures described here changes outcomes in this specific population. They are supported by anatomical evidence and by the insulin literature; a trial in incretin users has not been done and probably will not be.⁴

Readers who know of stability data or technique trials we have missed should write to standards@compoundjournal.com. This is one of the files where we would most like to be corrected, because the current state is that millions of injections a week are being given on the basis of transferred evidence and a four-line calculation.

A last word on the market. The arithmetic here is exact and the input to it is not. Every calculation begins with a stated mass of peptide, and where content has not been independently measured that figure is a claim rather than a specification. Perfect technique performed on an unmeasured vial delivers an unknown dose very accurately, and readers should hold both halves of that sentence at once.